FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
– 77% Overall Response Rate in RET Fusion Cancers and 45% Overall Response Rate in RET Mutated Medullary...
– PDUFA date set for November 26, 2018 – STAMFORD, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology...
– LOXO-292 Phase 1 Clinical Trial Abstract Selected for “Best of ASCO” – – Company to Host Conference Call...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.